Please Wait
Applying Filters...
menu
    • menu
    CDMO Activity Tracker: Lupin’s CDMO commissions oncology block in India; Cambrex, Axplora, Hovione expand operations

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    Letermovir [INN]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,656Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    29/11/2025 Honour Lab Limited
    India
    		 HONOUR LAB LTD 41441 LETERMOVIR (AMORPHOUS) 2025-06-29 Active II Complete 2025-11-03 2025-09-15
    12/12/2025 Lupin Manufacturing Solutions
    India
    		 LUPIN MANUFACTURING SOLUTIONS LTD 35981 LETERMOVIR 2021-06-10 Active II Complete 2021-07-06 2021-06-16
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.